Recent Blog Articles

Trial fails to enhance cholesterol drug's reputation

Updated: April 01, 2008

Trial fails to enhance cholesterol drug's reputation

Vytorin comes under fire after trial shows it works no better than a statin.

The media firestorm that torched the cholesterol-lowering drug Vytorin in January 2008 showed just how hot the topic of new drugs is today. Trial results showing that the FDA-approved drug was no better than a generic statin at keeping artery-clogging plaque in check had some commentators calling for a moratorium on the use of the drug. Headlines such as "Cholesterol drug bombs" and "Vytorin May Increase Risk of Heart Attack or Stroke" prompted thousands of worried Vytorin takers to call their doctors.

To continue reading this article, you must log in.

Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.

  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »

I'd like to receive access to Harvard Health Online for only $4.99 a month.

Sign Me Up

Already a member? Login ».

Disclaimer:

As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.